Alvar Agusti, José Luis Lopez-Campos, Marc Miravitlles, Juan Jose Soler-Cataluña, Jose Maria Marin, Borja G Cosio, Bernardino Alcázar-Navarrete, Jose Maria Echave-Sustaeta, Ciro Casanova, German Peces-Barba, Juan Pablo de-Torres, Alberto Fernandez-Villar, Julio Ancochea, Felipe Villar-Alvarez, Miguel Roman-Rodriguez, Jesus Molina, Juan Luis Garcia-Rivero, Cruz Gonzalez, Patricia Sobradillo, Rosa Faner, Carolina Peña, Raj Sharma, Bartolome R Celli
INTRODUCTION: Treatment with LABA/LAMA is recommended in GOLD B patients. We hypothesized that triple therapy (LABA/LAMA/ICS) will be superior to LABA/LAMA in achieving and maintaining clinical control (CC), a composite outcome that considers both impact and disease stability in a subgroup of GOLD B patients (here termed GOLD B+ patients) characterized by: (1) remaining symptomatic (CAT≥10) despite regular LABA/LAMA therapy; (2) having suffered one moderate exacerbation in the previous year; and (3) having blood eosinophil counts (BEC) ≥150cells/μL...
April 25, 2024: Archivos de Bronconeumología